
    
      The investigators select 60 cases of women with breast cancer at clinical stage of
      T1-4N0-2M0. Then treat them with 4 cycles of TAC (Abraxane 260mg/m2,EPI 60 mg/m2 ,CTX 500
      mg/m2, 21day/cycle) as neoadjuvant chemotherapy. Finally the investigators assess the
      efficacy and safety of Albumin-bound Paclitaxel.
    
  